R Squared’s Praxis Precision Medicines PRAX Stock Holding History

R Squared’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-90	Closed	-$6.93K	–	1187
2024 Q4	$6.93K	Buy	+90	New	+$6.51K	0.01%	1246

Other funds holding PRAX

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

R Squared's PRAX Position: Q1 2025 in Review

R Squared sold out of Praxis Precision Medicines (PRAX) in Q1 2025, closing a stake of 90 shares — an estimated $6.93K sold.

R Squared first reported a position in PRAX in Q4 2024 and held it in 1 quarter. The position peaked at $6.93K in Q4 2024. 150 funds tracked by Wall St. Rank hold PRAX as of Q1 2025.

R Squared reported no remaining Praxis Precision Medicines position as of Q1 2025 after selling out during the quarter.
R Squared sold 90 Praxis Precision Medicines shares in Q1 2025, an estimated $6.93K.
R Squared first reported a position in Praxis Precision Medicines in Q4 2024 and held it in 1 quarter.
R Squared's Praxis Precision Medicines position peaked at $6.93K in Q4 2024.
150 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.